New York City's nascent biotech investment fund is ready to get rolling, recruiting some venture capital partners to join Eli Lilly, Celgene and GE Ventures with hopes of pouring $150 million into the local life sciences startup scene.
A big venture round led by Sofinnova Ventures and backed by a lengthy string of biotech stalwarts and public investment firms is bound to get tongues wagging again about a possible IPO in the near future for San Diego-based aTyr.
Durham, NC's Novan Therapeutics raised $50 million to bankroll a new treatment for acne, persuading the high-profile European investor Malin to buy into the idea.
Biotech VC stalwart Flagship Ventures put together a $537 million new fund, its largest ever, with eyes on a new generation of life sciences upstarts.
Joint Polish Investment Fund Management is claiming a first. The Warsaw, Poland-based group has reportedly become the country's first institutional venture capital fund dedicated to life sciences after it held the initial closing of its $42 million (€38 million) investment vehicle.
EP Vantage's Amy Brown joins FierceBiotech Radio to talk about her retrospective look at a big year for biotech and peek ahead at what might be in store for 2015.
Cambridge, MA, biotech Semma Therapeutics is developing a stem cell technology that could help diabetics return to producing their own insulin, and the nascent company picked up $44 million and a handshake with Novartis to get rolling.
Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.
The United Kingdom is to change the laws governing startup investment vehicles known as Venture Capital Trusts (VCTs) but has opted against some of the dramatic alterations previously mooted. VCTs will still face new restrictions on the companies to which they can provide private equity cash, though.
Nimbus Therapeutics is ready to see how the compounds it discovered with the help of Schrödinger's computational chemistry tools fare in the clinic. And the VC units of Eli Lilly, GlaxoSmithKline and Pfizer want to find out, too, prompting each to chip in to Nimbus' $43 million Series B round.